Got a Question?
If you have a question for our guest, host or DRG please submit it here.
Bringing together minds to combat COVID-19
Guest: Sir Mene Pangalos, Executive Vice President, AstraZeneca
In this fireside chat brought to you by Conversations in Healthcare, Mike Ward, Global Head of Thought Leadership at DRG talks to Sir Mene Pangalos, Executive Vice President at AstraZeneca. Sir Mene talks to Mike about AstraZeneca's learnings from helping Chinese colleagues combat Coronavirus at the end of 2019, and then expanding input as it became a global issue. This includes adapting existing molecules in their pipeline, utilizing their existing capabilities and keeping their supply chain moving. He also explains how the industry has come together like never before to collaborate and share ideas across the board. Sir Mene and Mike also discuss what the new normal for the pharma industry may look like in a post-pandemic world. Watch the full interview here.
About our Guest
Sir Mene Pangalos, Executive Vice President, AstraZeneca
Mene was appointed as Executive Vice-President, R&D BioPharmaceuticals in January 2019 and is responsible for BioPharmaceutical R&D from discovery through to late-stage development covering Cardiovascular, Renal, Metabolism, Respiratory, Inflammation, Autoimmune, Microbial Science and Neuroscience areas. Prior to this, he served as Executive Vice-President of AstraZeneca’s IMED Biotech Unit and Global Business Development.
Since joining AstraZeneca in 2010, Mene has led the transformation of R&D productivity through the development and implementation of the “5R” framework resulting in a greater than four-fold increase in success rates compared to industry averages. In parallel, he has championed an open approach to working with academic and other external partners, changing the nature of academic-industry collaboration. Mene previously held senior R&D roles at Wyeth and GSK.
About our Host
Mike Ward, Head of Thought Leadership, DRG
Mike Ward serves as Global Head of Thought Leadership at Decision Resources Group (DRG), part of Clarivate. As both a journalist and analyst, Mike has been writing, analyzing and commenting on the life sciences industry for more than 35 years. He has held editorial and content leadership roles at various publications and organizations across the industry.
